statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship...

Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental...

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadias Board of Directors (the Committee) granted inducement awards consisting of...

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology...

Acadia Pharmaceuticals Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

Latest Ratings for ACAD
 DateFirmActionFromTo Mar 2022Cantor FitzgeraldMaintainsOverweight Mar 2022Goldman SachsMaintainsNeutral Mar 2022MizuhoMaintainsNeutral
 View More Analyst Ratings for...

Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead...

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m...

Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares

A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have lost about 23.4% in that time frame, underperforming the S&P 500.Will the recent negative trend...

Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?

Expert Ratings For ACADIA Pharmaceuticals

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Volume	1.63M
52-Wk High	$33.99
52-Wk Low	$16.16

Period	Estimated	Reported	Surprise	Result
Q1'24	$0.05	--	--	N/A
Q4'23	$0.29	$0.28	-3.09%	MISSED
Q3'23	-$0.45	-$0.40	10.65%	BEAT
Q2'23	-$0.10	$0.01	110.22%	BEAT
Q1'23	-$0.21	-$0.27	-25.90%	MISSED

ACAD Acadia Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals